This study characterized CXC chemokine receptor 4 (CXCR4) expression in patients with mitral valve disease and chronic atrial fibrillation (AF). Forty-eight patients with chronic AF formed two groups based on whether they were treated with or without renin-angiotensin system (RAS) blockers (AF + RAS group; n = 25, or AF -RAS group; n = 23). The controls comprised 17 mitral valve disease patients with sinus rhythm (SR group). CXCR4 mRNA and protein levels in the left atria were significantly higher in the AF -RAS and AF + RAS groups than in the SR group. CXCR4 expression was significantly lower in the AF + RAS group than the AF -RAS group. More CD34 + cells expressed CXCR4 in the AF -RAS and AF + RAS groups than in the SR group. Angiotensin II, collagen I and left atrial diameter significantly positively correlated with CXCR4 expression in the AF -RAS group. These results suggest that CXCR4 expression is up-regulated in chronic AF patients with mitral valve disease, is associated with atrial remodelling, and that these effects are attenuated by RAS blockers.
Introduction
Chronic atrial fibrillation (AF) is characterized by a remodelling process that involves the development of myocardial fibrosis. 1 -3 Studies performed in animal models suggest that fibrosis is the result of disrepair, in which recruitment of a subpopulation of bone marrow (BM)-derived stem cells provides sources of active fibroblasts. 4, 5 The CXC chemokine receptor 4 (CXCR4) is a unique chemo-attractant for a broad range of cell types, including BMderived stem cells. 6, 7 There is evidence that CXCR4 could be involved in several pathological conditions such as myocardial infarction, 8 pulmonary fibrosis 9 and myelofibrosis; 10 these studies all appear to support the premise that the regulation of CXCR4 could contribute to the increased atrial fibrosis that is observed in the process XX Wang, FR Zhang, JH Zhu et al.
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of chronic AF. 8 -10 The aim of this study was to investigate and characterize CXCR4 expression profiles in chronic AF patients with mitral valve disease.
Patients and methods

PATIENTS AND TREATMENTS
Consecutive patients with chronic atrial fibrillation (diagnosed > 6 months previously) and mitral valve disease, who were undergoing cardiac surgery for mitral valve replacement, were recruited from the Department of Thoracic Surgery at The First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, China. Patients were excluded if they had additional cardiac diseases such as: coronary artery disease; New York Heart Association class 3 or 4 congestive heart failure; reninangiotensin system (RAS) blocker treatment (including angiotensin-converting enzyme inhibitor [ACEi] or angiotensin receptor blocker [ARB] therapy) within the past month; or other serious systemic diseases.
Eligible patients were divided into two groups: the AF -RAS group was not being treated with RAS blockers; the AF + RAS group was being treated with RAS blockers. Patients with mitral valve disease with sinus rhythm, who were not being treated with an ACEi or ARB, served as the matched control (SR) group. The patients with AF had received anti-coagulant treatment with individually adjusted doses of warfarin for ≥ 4 weeks.
All patients were investigated by routine cardiological examinations including X-ray, echocardiography and electrocardiography (ECG) before enrolment. Echocardiographic acquisition and analyses were performed by experienced echocardiographers blinded to the clinical data. Left atrial tissue samples were obtained at the same stage of surgical procedure during extracorporeal circulation, then immediately frozen in liquid nitrogen and stored at -80°C until further analysis.
The study protocol was approved by the ethics review board of the First Affiliated Hospital, Medical School of Zhejiang University. Informed consent was obtained from all individuals or their guardians, according to the Declaration of Helsinki and the relevant policies in China.
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
Total RNA was extracted using a TRIzol ® kit (Gibco™ BRL, Gaithersburg, MD, USA). Reverse transcription (RT) was performed using 2 µg total RNA that was reverse transcribed into cDNA using oligo(dT) primer, then amplified using the following specific primers: CXCR4, AATCTTCCTGC CCACCATCT and GACGCCAACATAGACCA CCT; collagen I, AGTGGTTACTACTGGAT TGACC and TTGCCAGTCTCCTCATCC; and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), GAAGGTGAAGGTCGGAGTC and GAAGATGGTGATGGGATTTC.
The number of polymerase chain reaction (PCR) cycles for each gene was chosen to fall in the exponential phase of amplification. The PCR conditions were: 94°C for 30 s, 55°C for 30 s and 72°C for 1 min. The PCR products were run on a 1.0% agarose gel and stained with ethidium bromide. Results were expressed as a ratio of expression of the target gene to that of GAPDH (internal standard housekeeping gene).
WESTERN BLOT ANALYSIS
Whole-cell lysates were isolated from atrial tissue in radioimmunoprecipitation assay buffer (50 mmol/l Tris-HCl [pH 7.4], 150 mmol/l NaCl, 1% NP-40, 0.1% sodium dodecyl sulphate [SDS] and protease inhibitors) and centrifuged at 12 000 g for 10 min at 4°C. Samples (50 µg total protein) XX Wang, FR Zhang, JH Zhu et al.
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were fractionated by 4 -20% gradient SDS polyacrylamide gel electrophoresis and transblotted onto nitrocellulose filters (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membrane was incubated overnight at 4°C using the following mouse antibodies: anti-CXCR4 (diluted to 1:1000; R&D Systems, Minneapolis, MN, USA) and anti-β-actin (1:2000; Sigma-Aldrich, St Louis, MO, USA). The membranes were then incubated for 1 h in the appropriate diluted secondary antibody. Signal was detected using an electrochemiluminescence (ECL) kit (GE Healthcare, Little Chalfont, UK). Exposed films were quantified on an automated imaging system (Eastman Kodak™, Rochester, NY, USA). A molecular weight marker (Invitrogen™, Carlsbad, CA, USA) was used to estimate the molecular weight of CXCR4.
ANGIOTENSIN II CONCENTRATION IN ATRIAL TISSUE
Atrial tissues were lysed in ice-cold buffer containing 50 mmol/l Tris, 150 mmol/l NaCl, 5 mmol/l ethylenediaminetetraacetic acid (EDTA), 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/l phenylmethylsulphonyl fluoride, 10 mg/l aprotinin, and 1 mmol/l sodium orthovanadate. Insoluble material was removed by centrifugation at 12 000 g for 15 min at 4°C and stored at -80°C until further analysis. The concentration of angiotensin II in the atrial tissue was quantified using a radioimmunoassay kit (Beijing Chemclin Biotech, Beijing, China) according to the manufacturer's instructions.
FLOW CYTOMETRY
Cell surface expression of CXCR4 was evaluated by flow cytometry using anti-CXCR4 phycoerythrin (PE)-conjugated antibodies (eBioscience, San Diego, CA, USA). The CD34 + cells isolated from human peripheral blood mononuclear cells were positively selected using the MiniMACS™ immunomagnetic separation system (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. EDTA-anticoagulated blood (100 µl) was stained with anti-CXCR4 PEconjugated antibodies. Cells incubated with isotype control mouse immunoglobulin (Ig) G2a served as negative controls. After red cell lysis, the samples were centrifuged and the pellets resuspended in 300 µl saline. Cells (2 × 10 5 ) were analysed by flow cytometry, using CellQuest™ software (Becton Dickinson, San Jose, CA, USA) and expressed as the mean percentage of CXCR4expressing CD34 + cells in each group.
STATISTICAL ANALYSIS
Data are expressed as the mean ± SE. Categorical variables were compared using the χ 2 test or Fisher's exact test. Continuous variables were compared using one-way analysis of variance and the Bonferroni multiple comparisons procedure. The Pearson correlation was calculated for correlation analysis. A P-value < 0.05 was considered statistically significant.
Results
A total of 48 AF patients with mitral valve disease participated in the study: 23 patients were included in the AF -RAS group, 25 in the AF + RAS group of which 17 patients had received an ACEi (benazepril, n = 6; cilazapril, n = 3; perindopril, n = 3; captopril, n = 2; ramipril, n = 2; fosinopril, n = 1) and eight had received an ARB (irbesartan, n = 3; valsartan, n = 2; losartan, n = 2; candesartan, n = 1), and 17 mitral valve disease patients with sinus rhythm formed the control (SR) group. The mean ± SE period of treatment before enrolment was 13.2 ± 5.9
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months. There were no significant differences in age, gender, left ventricular ejection fraction, and calcium antagonist and β-blocker use among the three groups. Left atrial diameter in chronic AF patients with or without RAS blocker treatment was significantly larger than that in the control SR group (both P < 0.05). The clinical parameters of the patient population are summarized in Table 1 .
As shown in Fig. 1 , CXCR4 mRNA and protein levels in the left atria were significantly higher in both the AF -RAS and AF + RAS groups than in the control SR group (P < 0.05), with expression significantly down-regulated in the AF + RAS group compared with the AF -RAS group (P < 0.05). Flow cytometry showed that 66.15 ± 3.70% and 52.73 ± 3.49% of CD34 + mononuclear cells expressed CXCR4 in the AF -RAS and AF + RAS groups, respectively (P < 0.05); whereas only 25.48 ± 2.26% of CD34 + cells expressed CXCR4 in the control SR group (P < 0.05 vs control SR group; Fig. 2 ). In addition, there were significant positive correlations between the CXCR4 mRNA level and the level of angiotensin II, the level of collagen I mRNA and left atrial diameter in patients with chronic AF (r = 0.76, 0.65 and 0.52, respectively; all P < 0.05).
Discussion
To the best of our knowledge, the present study is the first to show that expression of CXCR4 is up-regulated in chronic AF patients with mitral valve disease. Moreover, CXCR4 expression was associated with atrial remodelling and was attenuated by RAS blockers.
It is well known that AF is associated with AF, atrial fibrillation; RAS, renin-angiotensin system; SR, patients with mitral valve disease with sinus rhythm who were not being treated with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker; AF -RAS, patients with chronic atrial fibrillation and mitral valve disease not being treated with RAS blockers; AF + RAS, patients with chronic atrial fibrillation and mitral valve disease who were treated with RAS blockers in the form of either an angiotensin-converting enzyme inhibitor (n = 17) or an angiotensin receptor blocker (n = 8). a P < 0.05 compared with control group; b P < 0.05 compared with AF-RAS group.
SR patients AF -RAS AF + RAS
TABLE 1: Clinical parameters of the patients with chronic atrial fibrillation and mitral valve disease and the control patients with mitral valve disease with sinus rhythm who participated in this study to characterize CXC chemokine receptor 4 expression Atrial fibrillation and CXC chemokine receptor 4 expression
pathophysiological modifications of the atria, such as structural remodelling. 1 -3 Structural remodelling might be one of the factors responsible for an enhanced stability of AF, characterized by increased collagen deposition. 11, 12 CXCR4 could influence scar formation in the damaged heart. 13, 14 The present study showed that correlations exist between increased CXCR4 expression and the markers of structural remodelling that we measured, namely angiotensin II and collagen I mRNA levels in atrial tissue and left atrial diameter. These findings imply that up-regulated CXCR4 might contribute to the process of AF through regulating atrial fibrosis and structural remodelling. In addition, the results suggest that CXCR4 in fibrillating atria could contribute to the therapeutic effects of RAS blockers. On the one hand, CXCR4 is a unique chemo-attractant for a broad range of cell types, including BM-derived stem cells. 6, 7 On the other hand, chronic AF appeared to increase the proportion of CD34 + haematopoietic progenitor cells. There were several limitations to the present study. First, it was largely designed to be descriptive and, therefore, could not clarify the signalling pathways and molecular interactions between CXCR4 and the RAS blockers. Secondly, because chronic AF patients inevitably took more medicines such as digitalis and anti-arrhythmic drugs, there could be some confounding effects on CXCR4 expression. Thirdly, it is important to mention that the AF patients in the present study might have been cardioverted at some point during the study period. It is difficult to track cardiac rhythm accurately and reflect the true burden of AF. 
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In conclusion, our findings suggest that CXCR4 over-expression might be important in the AF remodelling process and indicated CXCR4 to be implicated in the therapeutic mechanism of action of RAS blockers. 
